Skip to main content

Joint Diseases

1
Pipeline Programs
4
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Botulinum Toxin Type A 100UPhase 21 trial
Active Trials
NCT03726788Withdrawn0Est. Apr 2022
MicroPort
MicroPortChina - Shanghai
3 programs
EVOLUTION® NitrX™N/A1 trial
PROFEMUR® Preserve Classic Femoral StemN/A1 trial
Total Hip Arthroplasty ImplantN/A1 trial
Active Trials
NCT04816773Enrolling By Invitation150Est. Jan 2035
NCT04615039Withdrawn0Est. Dec 2033
NCT04147559Enrolling By Invitation150Est. Nov 2033
Ortho Development
1 program
Routine Total Hip ArthroplastyN/A1 trial
Active Trials
NCT03986918Unknown400Est. Jun 2024
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
oxycodone CRPHASE_31 trial
Active Trials
NCT00784277Completed597Est. Jul 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Johnson & Johnsonoxycodone CR
AbbVieBotulinum Toxin Type A 100U
MicroPortEVOLUTION® NitrX™
MicroPortPROFEMUR® Preserve Classic Femoral Stem
MicroPortTotal Hip Arthroplasty Implant
Ortho DevelopmentRoutine Total Hip Arthroplasty

Clinical Trials (6)

Total enrollment: 1,297 patients across 6 trials

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Start: Oct 2008Est. completion: Jul 2009597 patients
Phase 3Completed
NCT03726788AbbVieBotulinum Toxin Type A 100U

Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis

Start: Sep 2019Est. completion: Apr 20220
Phase 2Withdrawn
NCT04816773MicroPortEVOLUTION® NitrX™

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Start: Jan 2022Est. completion: Jan 2035150 patients
N/AEnrolling By Invitation
NCT04615039MicroPortPROFEMUR® Preserve Classic Femoral Stem

Post Market Clinical Follow-Up Study for MicroPort PROFEMUR® Preserve Classic Femoral Stem

Start: Dec 2021Est. completion: Dec 20330
N/AWithdrawn
NCT04147559MicroPortTotal Hip Arthroplasty Implant

Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem

Start: Oct 2020Est. completion: Nov 2033150 patients
N/AEnrolling By Invitation
NCT03986918Ortho DevelopmentRoutine Total Hip Arthroplasty

Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

Start: Jun 2019Est. completion: Jun 2024400 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.